Tremendous advancements in proteolysis targeting chimera (PROTAC) technology have been made in recent years. However, whether a covalent inhibitor-based PROTAC can be developed remains controversial. Here, we successfully developed chimeric degraders based on covalent inhibitors to degrade BTK and BLK kinases, demonstrating that covalent inhibitor-based PROTACs are viable and useful tools.

中文翻译：

---

通过基于共价抑制剂的PROTAC降解蛋白质。

近年来，针对嵌合体的蛋白水解（PROTAC）技术取得了巨大的进步。但是，是否可以开发基于共价抑制剂的PROTAC仍存在争议。在这里，我们成功开发了基于共价抑制剂的嵌合降解物，以降解BTK和BLK激酶，证明基于共价抑制剂的PROTAC是可行和有用的工具。